Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Kymera Therapeutics, Inc. - Common Stock (KYMR) Institutional Ownership
CUSIP: 501575104
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
252
Shares (Excl. Options)
89,844,491
Price
$77.81
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- KYMR on Nasdaq
- Shares outstanding
- 80,235,145
- Price per share
- $83.29
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 89,844,491
- Total reported value
- $6,991,141,975
- % of total 13F portfolios
- 0.01%
- Share change
- +9,115,698
- Value change
- +$715,972,868
- Number of holders
- 252
- Price from insider filings
- $83.29
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KYMR - Kymera Therapeutics, Inc. - Common Stock is tracked under CUSIP 501575104.
- 252 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 252 to 19 between Q4 2025 and Q1 2026.
- Reported value moved from $6,991,141,975 to $3,582,619.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 252 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 501575104?
CUSIP 501575104 identifies KYMR - Kymera Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501575104:
Significant Owners of Kymera Therapeutics, Inc. - Common Stock (KYMR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +38% | $694,720,745 | +$237,235,847 | 8,928,574 | +52% | FMR LLC | 31 Dec 2025 |
| BAKER BROS. ADVISORS LP | 11% | +14% | $551,236,913 | +$127,711,627 | 8,676,797 | +30% | Baker Bros. Advisors LP | 09 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.5% | $436,311,906 | 6,867,809 | BVF PARTNERS L P/IL | 11 Dec 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.1% | $288,530,046 | 5,097,704 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 5.5% | -28% | $322,541,273 | -$70,102,666 | 4,412,933 | -18% | Wellington Management Group LLP | 31 Dec 2025 |
| BlackRock, Inc. | 5.4% | $165,983,856 | 3,803,227 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 252 institutional investors reported holding 89,844,491 shares of Kymera Therapeutics, Inc. - Common Stock (KYMR). This represents 112% of the company’s total 80,235,145 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kymera Therapeutics, Inc. - Common Stock (KYMR) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 8,928,574 | +52% | 0.04% | $694,732,353 |
| BAKER BROS. ADVISORS LP | 11% | 8,657,242 | +30% | 3.9% | $673,620,000 |
| Avoro Capital Advisors LLC | 9.3% | 7,474,747 | +18% | 5.7% | $581,610,064 |
| VANGUARD GROUP INC | 7.8% | 6,267,644 | +16% | 0.01% | $487,685,380 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.7% | 6,159,335 | +21% | 0.05% | $479,258,000 |
| BVF INC/IL | 6.9% | 5,502,710 | 0% | 14% | $428,165,865 |
| BlackRock, Inc. | 6.2% | 5,004,095 | +15% | 0.01% | $389,368,651 |
| Atlas Venture Life Science Advisors, LLC | 5.8% | 4,659,874 | -4.8% | 42% | $362,584,796 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.5% | 4,412,933 | -15% | 0.06% | $343,370,317 |
| Siren, L.L.C. | 4.1% | 3,286,830 | -4.1% | 7.6% | $255,748,242 |
| STATE STREET CORP | 2.8% | 2,209,837 | +9.4% | 0.01% | $171,947,417 |
| Capital Research Global Investors | 1.9% | 1,560,791 | +24% | 0.02% | $121,445,148 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,417,389 | +11% | 0.01% | $110,306,963 |
| Driehaus Capital Management LLC | 1.3% | 1,069,238 | +14% | 0.57% | $83,197,409 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 952,065 | +1852% | 0.02% | $74,080,178 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.1% | 912,498 | +5.6% | 0.02% | $71,001,470 |
| Merck & Co., Inc. | 0.96% | 772,165 | 0% | 22% | $60,082,159 |
| FEDERATED HERMES, INC. | 0.95% | 763,920 | +37% | 0.1% | $59,440,615 |
| Holocene Advisors, LP | 0.95% | 761,209 | -9.4% | 0.12% | $59,229,672 |
| Commodore Capital LP | 0.93% | 750,000 | 0% | 3.9% | $58,357,500 |
| GOLDMAN SACHS GROUP INC | 0.92% | 740,306 | +4.1% | 0.01% | $57,603,210 |
| UBS Group AG | 0.92% | 737,032 | +14% | 0.01% | $57,348,460 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 0.79% | 635,957 | +23% | 0.53% | $49,483,814 |
| T. Rowe Price Investment Management, Inc. | 0.78% | 629,745 | +3% | 0.03% | $49,001,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.78% | 626,430 | -2.8% | 0.76% | $48,742,648 |
Institutional Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 43,016 | $3,582,619 | -$1,443,279 | $83.29 | 19 |
| 2025 Q4 | 89,844,491 | $6,991,141,975 | +$715,972,868 | $77.81 | 252 |
| 2025 Q3 | 80,864,737 | $4,576,806,879 | +$137,276,130 | $56.60 | 207 |
| 2025 Q2 | 78,801,021 | $3,438,754,240 | +$270,821,262 | $43.64 | 208 |
| 2025 Q1 | 72,808,716 | $1,995,263,098 | +$5,348,226 | $27.37 | 171 |
| 2024 Q4 | 71,721,890 | $2,885,022,540 | +$14,409,751 | $40.23 | 177 |
| 2024 Q3 | 69,051,239 | $3,268,392,680 | +$183,360 | $47.33 | 174 |
| 2024 Q2 | 67,390,465 | $2,011,640,213 | +$5,551,590 | $29.85 | 153 |
| 2024 Q1 | 67,207,302 | $2,701,742,064 | +$296,832,171 | $40.20 | 161 |
| 2023 Q4 | 60,455,852 | $1,539,280,108 | +$89,020,891 | $25.46 | 134 |
| 2023 Q3 | 57,350,132 | $797,188,696 | -$18,249,775 | $13.90 | 120 |
| 2023 Q2 | 58,230,116 | $1,338,678,295 | +$29,100,921 | $22.99 | 124 |
| 2023 Q1 | 56,859,649 | $1,683,467,091 | +$23,131,891 | $29.63 | 123 |
| 2022 Q4 | 56,195,243 | $1,402,708,961 | +$98,529,765 | $24.96 | 116 |
| 2022 Q3 | 52,859,306 | $1,150,805,258 | +$29,150,428 | $21.77 | 119 |
| 2022 Q2 | 49,442,050 | $973,574,555 | +$16,502,218 | $19.69 | 99 |
| 2022 Q1 | 45,688,568 | $1,933,296,396 | +$62,437,636 | $42.32 | 124 |
| 2021 Q4 | 43,015,870 | $2,729,867,438 | +$128,644,677 | $63.49 | 123 |
| 2021 Q3 | 34,637,185 | $2,035,073,191 | +$491,859,746 | $58.74 | 115 |
| 2021 Q2 | 26,479,657 | $1,284,263,574 | +$188,105,374 | $48.50 | 109 |
| 2021 Q1 | 22,191,421 | $862,345,865 | +$92,686,286 | $38.86 | 94 |
| 2020 Q4 | 20,299,967 | $1,247,002,136 | +$53,009,741 | $62.00 | 74 |
| 2020 Q3 | 16,828,031 | $542,529,000 | +$542,529,000 | $32.31 | 51 |